EUROATLANTIC-AIRWAYS
17.4.2024 09:01:28 CEST | Business Wire | Press release
euroAtlantic Airways – Transportes Aereos S.A. (“euroAtlantic”, “EAA” or “the Company”), the Portuguese aircraft wet-leasing and charter business, today announces that Stewart Higginson has been appointed CEO and Chair of euroAtlantic and will be joined by the highly experienced management team of Mário Alvim, Lourenço Gomes and João Nunes, who will complete the Board.
Alongside the Board changes, Njord I-Jet Aviation S.A.R.L ("Njord I-Jet"), which owns a controlling interest in EAA, has committed further funding to the Company, demonstrating Njord I-Jet’s confidence in the positive outlook for the business and positioning EAA for growth as it enters the next important phase in its development. The management team’s focus will be on optimising performance improvements and expanding the Company’s current fleet of five Boeing aircraft to meet demand and improving its market-leading ACMI and charter services.
Stewart has deep experience of delivering operational performance improvements in companies across multiple sectors. He has been an Operating Partner with Njord Partners since February 2015, during which time he has held a number of key leadership roles including CEO of Geoquip Marine and CEO of Nuova Deroma, and has held a number of board roles as both a director and Chair. Stewart has received multiple awards and nominations for his instrumental roles in corporate restructurings and turnarounds, including International Turnaround of the Year for DeepOcean in 2012, and for Solidal in 2020. Stewart was a Director at Alix Partners for nine years and is a member of the UK Institute for Turnaround.
Mário, Lourenço and João collectively have more than 40 years’ experience at euroAtlantic and c. 100 years of experience in the aviation industry. Mário is euroAtlantic’s Chief Pilot and has been at the Company since its founding year (1993). He started his career at Air Atlantis. Lourenço is Chief Operations Officer. He joined the Company in March 2016, having previously held management positions at TAP. He started his career as a pilot for Portugalia Airlines, TAP Portugal and Emirates. João rejoined euroAtlantic in March 2023, after having previously worked for euroAtlantic between 2004 and 2008 and holds the role of Accountable Manager. His 25+ year career in aviation includes experienced roles at TAP, Netjets and JetCapitalAviation, where he was Airworthiness Manager and Deputy Accountable Manager.
Njord I-Jet is wholly owned by funds managed by Njord Partners LLP, a long-term investor in the Western European middle-market with significant and proven expertise in successful turnarounds. Njord Partners has assets under management in excess of €1 billion, providing capital solutions and actively facilitating strategic and operational enhancements within its portfolio companies to drive value for all stakeholders.
Stewart Higginson, euroAtlantic CEO and Chair, commented: “I am delighted to be joining euroAtlantic, where I look forward to working with the new Board to drive the next phase of euroAtlantic’s growth and deliver a world-class ACMI and charter solutions business.”
Jakob Kjellberg, Co-Founder and Co-Portfolio Manager at Njord Partners, said: “We are excited about the future prospects of well capitalized EAA under new leadership. The Company couldn’t have anyone better than Stewart and the team to lead it through its ongoing transformation and deliver high quality, cost effective and flexible services to our valued customers. Stewart’s experience in optimising operations and performance is second-to-none and we know the business will thrive with him in this new role.”
About euroAtlantic Airways
euroAtlantic Airways is a Portuguese airline specializing in ACMI and charter solutions, operating a diverse fleet of aircraft. Headquartered in Carnaxide and based at Lisbon Airport, it offers charter services, wet-lease, and Ad-Hoc flights across the globe, and has served 719 Airports in 176 countries in 30 years of operations. euroAtlantic Airways was acquired a consortium including Njord Partners, in November 2019.
To find out more visit: https://www.euroatlantic.pt/en/quem-somos/
About Njord Partners
Njord Partners is a European special situations investment manager and provider of long-term flexible capital solutions, primarily to family-owned businesses. Established in 2013, Njord Partners has invested in 24 businesses and manages capital in excess of €1 billion. The Njord team has led turnarounds of over 25 companies located in 9 different jurisdictions, spanning 8 separate industries.
To find out more visit: https://njordpartners.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417583477/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom